Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data comparing PLC8024 CD133+ and CD133- HCC cells

ABSTRACT: To identify candidate genes involved in enhanced tumorigenicity of CD133+ liver tumor-initiating cells Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line PLC8024 was sorted into CD133+ and CD133- populations by flow cytometry

ORGANISM(S): Homo sapiens

SUBMITTER: Stephanie Ma

PROVIDER: E-GEOD-23451 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.

Tang Kwan Ho KH Ma Stephanie S Lee Terence K TK Chan Yuen Piu YP Kwan Pak Shing PS Tong Carol M CM Ng Irene O IO Man Kwan K To Ka-Fai KF Lai Paul B PB Lo Chung-Mau CM Guan Xin-Yuan XY Guan Xin-Yuan XY Chan Kwok Wah KW

Hepatology (Baltimore, Md.) 20120113 3

<h4>Unlabelled</h4>A novel theory in the field of tumor biology postulates that cancer growth is driven by a population of stem-like cells, called tumor-initiating cells (TICs). We previously identified a TIC population derived from hepatocellular carcinoma (HCC) that is characterized by membrane expression of CD133. Here, we describe a novel mechanism by which these cells mediate tumor growth and angiogenesis by systematic comparison of the gene expression profiles between sorted CD133 liver su ...[more]

PMID: 21994122

Similar Datasets

Expression data comparing Huh7 CD133+ and CD133- HCC cells

Project description:To identify candidate genes involved in enhanced tumorigenicity of CD133+ liver tumor-initiating cells Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line Huh7 was sorted into CD133+ and CD133- populations by flow cytometry

2012-04-04 | E-GEOD-23450 | biostudies-arrayexpress

Expression data comparing KYSE-140 ESCC cell line CD90+ and CD90- cells

Project description:To identify candidate genes involved in enhanced tumorigenicity and metastasis of CD90+ esophageal tumor-initiating cells. The esophageal squamous carcinoma cell (ESCC) cell line KYSE-140 was sorted into CD90+ and CD90- populations by flow cytometry. Total RNA was analyzed on Affymetrix Human Genome U133 Plus GeneChip 2.0 arrays.

2013-03-23 | E-GEOD-37949 | biostudies-arrayexpress

Expression data comparing chemoresistant (cisplatin and doxorubicin) hepatospheres and differentiated HCC cells

Project description:To identify candidate genes that are up-regulated in chemoresistant (cisplatin and doxorubicin) hepatospheres as compared with their differentiated counterparts Affymetrix Human Genome U133 Plus GeneChip 2.0 PLC/PRF/5 HCC cells were grown as spheroids and treated with cisplatin and doxorubicin combination. Differentiated counterparts were generated by addition of FBS in the spheroids and allowed to attach.

2014-06-01 | E-GEOD-53005 | biostudies-arrayexpress

Expression data comparing Huh7 control and CD47 knockdown cells

Project description:To identify candidate genes regulated by CD47 Affymetrix Human Genome U133 Plus GeneChip 2.0 HCC cell line Huh7 cells with or without CD47 repressed

2014-06-01 | E-GEOD-47563 | biostudies-arrayexpress

CD133- HCC cells infected with miR-130b vs. empty vector control

Project description:To identify candidate downstream mRNA target for hsa-miR-130b miR-130b or empty vector control was overexpressed in PLC8024 CD133- HCC cells using lentivirus

2010-12-10 | E-GEOD-17386 | biostudies-arrayexpress

Expression data comparing Huh7 cells transduced with shRNA CD24 (knockdown) or non-target control

Project description:To identify CD24 signaling pathway Affymetrix Human Genome U133 Plus GeneChip 2.0 shRNA CD24 (knockdown) or non-target control (NTC) was stably transduced into Huh7 HCC cells by lentiviral approach

2012-01-01 | E-GEOD-28057 | biostudies-arrayexpress

Expression data comparing Hep3B Caveolin-1 (Cav1) knockdown cells with Hep3B non-target control cells

Project description:To identify genes regulated by Cav1 Affymetrix Human Genome U133 Plus 2.0 GeneChip Hep3B cells with or without knockdown of Cav1

2016-03-01 | E-GEOD-75994 | biostudies-arrayexpress

Comparison of gene expression between CD133+ and CD133- SW620 human colon cancer cells

Project description:CD133 has been widely used for identification and isolation of cancer stem cells in tumors although its role as a marker for cancer stem cell is still controversial . We isolated the CD133+ and CD133- cells from SW620 human colon cancer cell line and compared their biological characteristics, such as tumorigenicity,drug sensitivity, etc. Our study revealed that CD133+ SW620 cells were more tumorigenic and resistant to anti-cancer drugs. Correspondingly, they displayed different gene expression profile. However, it was observed that CD133- cells and CD133+ cells could mutually convert, indicating that CD133 expression was under dynamic and reversible regulations which might impose significant infulence on cells behaviors. Thus, our data challenge the role of CD133 as a marker for cancer stem cell. There are two populations with distinct expression of CD133 in SW620 human colon cancer cell line. Microarray assays were employed to investigate the differentially expressed genes between the two populations, which may possess different tumorigenetic potential and sensitivity to anti-cancer drugs. CD133+ and CD133- cells were isolated from human colon cancer SW620 cell line by magnetic cell sorting system. The clones from sorted CD133+ or CD133- populations were established. Clone cells were expanded and were further purified by using CD133 cell isolation kit before microarray assays.

2010-07-29 | E-GEOD-23295 | biostudies-arrayexpress

Expression by CD133+ cells isolated from the adult human exocrine pancreas

Project description:Expression from CD133+ cells isolated from adult human exocrine tissue was compared to a CD133-depleted cell population Islet-depleted exocrine tissue from three independent adult human cadaveric pancreata were cultured for four days in Miami media 1A. Following trypsinization, cells were isolated using anti-CD133 immunomagnetic beads to >95% CD133+. CD133-negative cells were further depleted of CD133+ cells to <1% CD133+.

2016-01-15 | E-GEOD-64854 | biostudies-arrayexpress

Expression data from CD133+ and CD133- glioma cells

Project description:Given the very substantial heterogeneity of most human cancers, it is likely that most cancer therapeutics will be active in only a small fraction of any population of patients. As such, the development of new therapeutics, coupled with methods to match a therapy with the individual patient, will be critical to achieving significant gains in disease outcome. One such opportunity is the use of expression signatures to identify key oncogenic phenotypes that can serve not only as biomarkers but also as a means of identifying therapeutic compounds that might specifically target these phenotypes. Given the potential importance of targeting tumors exhibiting a stem-like phenotype, we have developed an expression signature that reflects common biological aspects of various stem-like characteristics. The Consensus Stemness Ranking (CSR) signature is upregulated in cancer stem cell enriched samples, at advanced tumor stages and is associated with poor prognosis in multiple cancer types. Using two independent computational approaches we utilized the CSR signature to identify clinically useful compounds that could target the CSR phenotype. In vitro assays confirmed selectivity of several predicted compounds including topoisomerase inhibitors and resveratrol towards breast cancer cell lines that exhibit a high-CSR phenotype. Importantly, the CSR signature could predict clinical response of breast cancer patients to a neoadjuvant regimen that included a CSR-specific agent. Collectively, these results suggest therapeutic opportunities to target the CSR phenotype in a relevant cohort of cancer patients. CD133+ and CD133- cells were separated from two glioma xenograft tumors. Both CD133+ and CD133- glioma cells were cultured in serum-free media for 48 hours in the presence of absence of laminin.

2010-10-16 | E-GEOD-24716 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data